Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Abstract

Background and Aims

Chronic kidney disease (CKD) patients suffer from high cardiovascular morbidity and mortality. Arterial stiffness is an important parameter for the evaluation of cardiovascular risk. Carotid-femoral pulse wave velocity (cfPWV) is the gold standard measure for the assessment of arterial stiffness. CHA2DS2-VASc score was originally used to predict cerebral infarction in patients with atrial fibrillation (AF). However, it is also useful in predicting outcome in different cardiovascular conditions, independent of the presence of AF. Therefore, the aim of our research was to assess the association of CHA2DS2-VASc score with cfPWV in CKD patients.

Method

Eighty-seven non-dialysis CKD patients from our outpatient clinic were included. At the time of inclusion, medical history data and standard blood results were collected, CHA2DS2-VASc score was calculated, cfPWV measurements (SphygmoCor System) were done. Correlation between CHA2DS2-VASc score and cfPWV was assessed. Multiple regression analysis with cfPWV as dependent and CHA2DS2-VASc score, eGFR, urinary albumin/creatinine, haemoglobin, high sensitivity CRP, serum calcium, phosphate and intact PTH as independent variables was performed. Additionally, patients were divided into two groups according to median value of CHA2DS2-VASc score (group 1: CHA2DS2-VASc score ≤2, group 2: CHA2DS2-VASc score >2). Data of both groups were compared by t-test or Mann-Whitney test.

Results

CHA2DS2-VASc score correlated with cfPWV (r=0.380, p=0.001). In multiple regression analysis only CHA2DS2-VASc score was significantly associated with cfPWV (p=0.001). Data of both groups of patients divided according to median value of CHA2DS2-VASc score are presented in table 1. cfPWV was significantly higher in group 2 (13.40±3.50 vs 10.46±2.93, p=0.001). Groups of patients also differed significantly in age, presence of diabetes, eGFR and serum phosphate.

Conclusion

CHA2DS2-VASc score is associated with cfPWV in CKD patients. Patients with a higher CHA2DS2-VASc score have stiffer arteries.

MO147   Table 1.
Open in new tab

Eighty-seven CKD patients were divided into two groups according to the median value of CHA2DS2-VASc score. Data are presented as mean±SD or as absolute number of patients with a known condition.

Group 1 (N=52) CHA2DS2-VASc score ≤2Group 2 (N=35) CHA2DS2-VASc score >2p
Age (years)53.98±10.4869.66±10.050.001
Sex - male/female37/1520/150.180
Arterial hypertension50350.243
Diabetes6160.001
Dyslipidaemia22210.108
Smoking - past or current27120.107
eGFR (ml/min/1.73m2)33.24±26.6323.95±12.980.034
Urinary albumin/creatinine (mg/g)859.94±1143.761048.37±1778.920.549
Haemoglobin (g/l)132.21±19.09125.26±17.020.086
High sensitivity CRP (mg/l)4.57±6.716.30±11.910.390
Calcium (mmol/l)2.23±0.152.23±0.130.864
Phosphate (mmol/l)1.17±0.331.32±0.380.046
Intact PTH (pg/ml)135.44±118.59144.88±97.950.704
Carotid-femoral pulse wave velocity (m/s)10.46±2.9313.40±3.500.001
Group 1 (N=52) CHA2DS2-VASc score ≤2Group 2 (N=35) CHA2DS2-VASc score >2p
Age (years)53.98±10.4869.66±10.050.001
Sex - male/female37/1520/150.180
Arterial hypertension50350.243
Diabetes6160.001
Dyslipidaemia22210.108
Smoking - past or current27120.107
eGFR (ml/min/1.73m2)33.24±26.6323.95±12.980.034
Urinary albumin/creatinine (mg/g)859.94±1143.761048.37±1778.920.549
Haemoglobin (g/l)132.21±19.09125.26±17.020.086
High sensitivity CRP (mg/l)4.57±6.716.30±11.910.390
Calcium (mmol/l)2.23±0.152.23±0.130.864
Phosphate (mmol/l)1.17±0.331.32±0.380.046
Intact PTH (pg/ml)135.44±118.59144.88±97.950.704
Carotid-femoral pulse wave velocity (m/s)10.46±2.9313.40±3.500.001
MO147   Table 1.
Open in new tab

Eighty-seven CKD patients were divided into two groups according to the median value of CHA2DS2-VASc score. Data are presented as mean±SD or as absolute number of patients with a known condition.

Group 1 (N=52) CHA2DS2-VASc score ≤2Group 2 (N=35) CHA2DS2-VASc score >2p
Age (years)53.98±10.4869.66±10.050.001
Sex - male/female37/1520/150.180
Arterial hypertension50350.243
Diabetes6160.001
Dyslipidaemia22210.108
Smoking - past or current27120.107
eGFR (ml/min/1.73m2)33.24±26.6323.95±12.980.034
Urinary albumin/creatinine (mg/g)859.94±1143.761048.37±1778.920.549
Haemoglobin (g/l)132.21±19.09125.26±17.020.086
High sensitivity CRP (mg/l)4.57±6.716.30±11.910.390
Calcium (mmol/l)2.23±0.152.23±0.130.864
Phosphate (mmol/l)1.17±0.331.32±0.380.046
Intact PTH (pg/ml)135.44±118.59144.88±97.950.704
Carotid-femoral pulse wave velocity (m/s)10.46±2.9313.40±3.500.001
Group 1 (N=52) CHA2DS2-VASc score ≤2Group 2 (N=35) CHA2DS2-VASc score >2p
Age (years)53.98±10.4869.66±10.050.001
Sex - male/female37/1520/150.180
Arterial hypertension50350.243
Diabetes6160.001
Dyslipidaemia22210.108
Smoking - past or current27120.107
eGFR (ml/min/1.73m2)33.24±26.6323.95±12.980.034
Urinary albumin/creatinine (mg/g)859.94±1143.761048.37±1778.920.549
Haemoglobin (g/l)132.21±19.09125.26±17.020.086
High sensitivity CRP (mg/l)4.57±6.716.30±11.910.390
Calcium (mmol/l)2.23±0.152.23±0.130.864
Phosphate (mmol/l)1.17±0.331.32±0.380.046
Intact PTH (pg/ml)135.44±118.59144.88±97.950.704
Carotid-femoral pulse wave velocity (m/s)10.46±2.9313.40±3.500.001
PDF
This content is only available as a PDF.
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Topic:
Issue Section:
Mini Orals (sorted by session) > Clinical nephrology
Download all slides

Comments

0 Comments
Comments (0)
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.